|Vaccines for Emerging Infectious Diseases Report 2018: Funding, R&D, and Global Partnership Strategies - ResearchAndMarkets.com|
|Friday, 11 January 2019 01:06|
Jan. 11, 2019 11:26 UTC
Vaccines for Emerging Infectious Diseases Report 2018: Funding, R&D, and Global Partnership Strategies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)-- The "Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies" report has been added to ResearchAndMarkets.com's offering.
"Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies" finds that philanthropic organizations and public-private partnerships like the Coalition for Epidemic Preparedness Innovations (CEPI) are filling a niche for funding translational and clinical vaccine research, allowing development of vaccines for diseases such as Lassa fever to occur even in the absence of an ongoing epidemic. As of November 2018, there were 235 vaccines in preclinical investigation, clinical development, or marketed for twelve major EIDs*.
Major EIDs include Zika, Ebola, MERS, Lassa, Marburg, Severe Acute Respiratory Syndrome (SARS), Chikungunya, CCHF, West Nile, Dengue, Yellow Fever, H5N1.
This report covers current and future challenges for the development and deployment of vaccines for EIDs, focusing on vaccine platform technology and research, funding mechanisms, and collaborative global partnerships.
Key Topics Covered:
2. Executive Summary
3. Overview of Emerging Infectious Diseases
4. Clinical Trial Design
5. Vaccine Platform Technologies
6. Funding and Market Incentives
7. Global Collaborations for Vaccine Development
8. Pipeline Vaccines for Key Emerging Infectious Diseases
9. Surveillance and Healthcare Infrastructures
For more information about this report visit https://www.researchandmarkets.com/research/zhwzpx/vaccines_for?w=4
Source: Research and Markets